Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | TNK2 | Q07912 | 6/20 | 0.35 |
| ▸ | POLRMT | O00411 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18636477 | 0.94 | TMPRSS2 (0.45) | TMPRSS2PRMT5WDR77TNK2POLRMT | |
| SCHEMBL25381965 | 0.89 | TMPRSS2 (0.47) | TMPRSS2PRMT5WDR77TNK2POLRMT | |
| SCHEMBL20144211 | 0.88 | TMPRSS2 (0.44) | TMPRSS2PRMT5WDR77TNK2POLRMT | |
| SCHEMBL16519861 | 0.87 | TMPRSS2 (0.49) | TMPRSS2PRMT5WDR77POLRMTRIPK1 | |
| SCHEMBL20878443 | 0.87 | TMPRSS2 (0.45) | TMPRSS2POLRMT | |
| SCHEMBL17722662 | 0.87 | TMPRSS2 (0.45) | TMPRSS2POLRMT | |
| SCHEMBL25383763 | 0.87 | TMPRSS2 (0.53) | TMPRSS2POLRMTRIPK1 | |
| SCHEMBL24606289 | 0.87 | TMPRSS2 (0.49) | TMPRSS2RIPK1 | |
| SCHEMBL26003158 | 0.87 | TMPRSS2 (0.50) | TMPRSS2POLRMT | |
| SCHEMBL24312542 | 0.86 | TMPRSS2 (0.49) | TMPRSS2POLRMTRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885PRMT5 1051/4885WDR77 1619/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885PRMT5 1051/4885WDR77 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.